Ac2IDU, BVDU, and thymine arabinoside therapy in experimental herpes keratitis.

Daniel Albert // Publications // Sep 01 1981

PubMed ID: 7283815

Author(s): Hettinger ME, Pavan-Langston D, Park NH, Albert DM, De Clercq E, Lin TS. Ac2IDU, BVDU, and thymine arabinoside therapy in experimental herpes keratitis. Arch Ophthalmol. 1981 Sep;99(9):1618-21. PMID 7283815

Journal: Archives Of Ophthalmology (Chicago, Ill. : 1960), Volume 99, Issue 9, Sep 1981

The therapeutic efficacy of three new antiviral agents-5-iodo-3′,5′-diacetyl-2′-deoxyuridine (diacetylidoxuridine, 1% Ac2IDU), E-5-(2-bromovinyl)-2′-deoxyuridine (0.25% BVDU), and 3% thymine arabinoside-is compared with available antivirals in an experimental model of herpes simplex virus type 1 (HSV-1) keratitis in New Zealand white rabbits. Compared with placebo, Ac2IDU significantly reduced ulcerative keratitis on days 4 through 8 after inoculation with virus and iritis on day 8 after inoculation. Compared with placebo, thymine arabinoside reduced ulcerative keratitis but not significantly. Thymine arabinoside caused significant iritis in all eyes. The epithelial disease in BVDU-treated eyes was significantly less than that in placebo-treated eyes on days 5 through 8 after inoculation. The results indicate that 1% Ac2IDU and 0.25% BVDU were effective in our ocular model of HSV-1 keratitis, whereas thymine arabinoside was not.